Urban Environmental Exposures and Childhood Cancer
NCT00505141 · Status: COMPLETED · Type: OBSERVATIONAL
Last updated 2007-07-23
Summary
The Environmental Protection Agency has recognized that organophosphorus pesticides require close regulation and continued monitoring for human health effects and some (e.g chlorpyrifos) have been phased-out from the consumer market due to the special risk that it posed for children. There is growing evidence in support of the association between pesticide exposure and childhood leukemia. Studies of pesticides and their association with childhood cancer have been limited by study designs, self-reporting and lack of biological measurements. While several large studies in California found little evidence of an association between agricultural pesticide use and childhood leukemia, these results are in contrast with the associations observed with household exposures to pesticides. The real association may depend on timing of exposure, type of pesticide, dose and pathway of exposure. Furthermore, some persons may be more susceptible to the effects of specific pesticides due to inherited mutations in their detoxification pathways.
We are conducting a pilot study to test the hypothesis that environmental exposure to pesticides in pregnancy or during the neonatal period, together with genetic susceptibility may lead to childhood ALL or brain cancer. The study is a multicenter, case-control study, based on collaboration between clinical researchers and basic science research to evaluate the risk for childhood cancer in relation to measured levels of pesticides (and their metabolites) and genetic polymorphisms. Biomarkers will be used to examine the risks of chronic low-dose exposures, and to characterize relationships between specific pesticides, childhood cancer and genetic susceptibility.
Hypothesis: Interaction between environmental factors (pesticides) and maternal or child genetic polymorphisms may lead to childhood cancer.
Conditions
Sponsors & Collaborators
-
Georgetown University
lead OTHER
Principal Investigators
-
Offie P Soldin · Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
Eligibility
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2004-09-30
- Completion
- 2006-02-28
Countries
- United States
Study Locations
More Related Trials
-
Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma
NCT00418327 ·Status: COMPLETED ·Phase: PHASE1
-
Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
NCT02512926 ·Status: COMPLETED ·Phase: PHASE1
-
Home Chemotherapy Intervention for Children With Cancer - a Feasibility Study
NCT05372536 ·Status: COMPLETED ·Phase: NA
-
Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases
NCT00513162 ·Status: COMPLETED ·Phase: PHASE1
-
Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer
NCT00053118 ·Status: COMPLETED ·Phase: PHASE1
-
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia
NCT00002704 ·Status: COMPLETED ·Phase: PHASE2
-
Role of Tumoral Biomarker B3 Adrenergic Receptor in Paediatric Solid Tumours
NCT06312150 ·Status: RECRUITING ·Phase: NA
-
Treatment of Acute Lymphoblastic Leukemia in Children
NCT00165178 ·Status: COMPLETED ·Phase: PHASE3
-
Epidemiology of Cardiotoxicity in Children With Cancer
NCT00005418 ·Status: COMPLETED
-
Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia
NCT00019409 ·Status: WITHDRAWN ·Phase: PHASE3
-
Effects of Oncological Treatment During Pregnancy on Mother and Child
NCT00330447 ·Status: RECRUITING
-
High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood
NCT00180791 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT02303821 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors
NCT04671901 ·Status: TERMINATED ·Phase: PHASE2
-
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
NCT00003273 ·Status: WITHDRAWN ·Phase: PHASE2
-
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia
NCT00002816 ·Status: COMPLETED ·Phase: PHASE3
-
Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents
NCT01535183 ·Status: UNKNOWN ·Phase: PHASE2
-
Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors
NCT00025077 ·Status: COMPLETED ·Phase: PHASE2
-
A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors
NCT00001502 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)
NCT00990912 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
NCT00004919 ·Status: COMPLETED ·Phase: PHASE1
-
Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma
NCT00020111 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma
NCT00025428 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years
NCT00936156 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors
NCT00281905 ·Status: UNKNOWN ·Phase: PHASE2